Skip to main content

Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study.

Publication ,  Journal Article
Oeffinger, KC; Stratton, KL; Hudson, MM; Leisenring, WM; Henderson, TO; Howell, RM; Wolden, SL; Constine, LS; Diller, LR; Sklar, CA; Nathan, PC ...
Published in: J Clin Oncol
July 10, 2021

PURPOSE: To determine the incidence of serious chronic health conditions among survivors of pediatric Hodgkin lymphoma (HL), compare by era of therapy and by selected cancer therapies, and provide estimates of risks associated with contemporary therapy. METHODS: Assessing 2,996 5-year HL survivors in the Childhood Cancer Survivor Study diagnosed from 1970 to 1999, we examined the cumulative incidence of severe to fatal chronic conditions (grades 3-5) using self-report conditions, medically confirmed subsequent malignant neoplasms, and cause of death based on the National Death Index. We used multivariable regression models to estimate hazard ratios (HRs) per decade and by key treatment exposures. RESULTS: HL survivors were of a mean age of 35.6 years (range, 12-58 years). The cumulative incidence of any grade 3-5 condition by 35 years of age was 31.4% (95% CI, 29.2 to 33.5). Females were twice as likely (HR, 2.1; 95% CI, 1.8 to 2.4) to have a grade 3-5 condition compared with males. From the 1970s to the 1990s, there was a 20% reduction (HR, 0.8; 95% CI, 0.7 to 0.9) in decade-specific risk of a grade 3-5 condition (P trend = .002). In survivors who had a recurrence and/or hematopoietic cell transplant, the risk of a grade 3-5 condition was substantially elevated, similar to that of survivors treated with high-dose, extended-field radiotherapy (HR, 1.2; 95% CI, 0.9 to 1.5). Compared with survivors treated with chest radiotherapy ≥ 35 Gy in combination with an anthracycline or alkylator, a contemporary regimen for low-intermediate risk HL was estimated to lead to a 40% reduction in risk of a grade 3-5 condition (HR, 0.6; 95% CI, 0.4 to 0.8). CONCLUSION: This study demonstrates that risk-adapted therapy for pediatric HL has resulted in a significant reduction in serious long-term outcomes.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

July 10, 2021

Volume

39

Issue

20

Start / End Page

2266 / 2275

Location

United States

Related Subject Headings

  • Young Adult
  • United States
  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Oeffinger, K. C., Stratton, K. L., Hudson, M. M., Leisenring, W. M., Henderson, T. O., Howell, R. M., … Robison, L. L. (2021). Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study. J Clin Oncol, 39(20), 2266–2275. https://doi.org/10.1200/JCO.20.01186
Oeffinger, Kevin C., Kayla L. Stratton, Melissa M. Hudson, Wendy M. Leisenring, Tara O. Henderson, Rebecca M. Howell, Suzanne L. Wolden, et al. “Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study.J Clin Oncol 39, no. 20 (July 10, 2021): 2266–75. https://doi.org/10.1200/JCO.20.01186.
Oeffinger KC, Stratton KL, Hudson MM, Leisenring WM, Henderson TO, Howell RM, et al. Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2021 Jul 10;39(20):2266–75.
Oeffinger, Kevin C., et al. “Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study.J Clin Oncol, vol. 39, no. 20, July 2021, pp. 2266–75. Pubmed, doi:10.1200/JCO.20.01186.
Oeffinger KC, Stratton KL, Hudson MM, Leisenring WM, Henderson TO, Howell RM, Wolden SL, Constine LS, Diller LR, Sklar CA, Nathan PC, Castellino SM, Barnea D, Smith SA, Hutchinson RJ, Armstrong GT, Robison LL. Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2021 Jul 10;39(20):2266–2275.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

July 10, 2021

Volume

39

Issue

20

Start / End Page

2266 / 2275

Location

United States

Related Subject Headings

  • Young Adult
  • United States
  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male